Santhera Pharmaceuticals Holding AG (SWX:SANN)
Switzerland
· Delayed Price · Currency is CHF 15.30
-0.94 (-5.79%)
Mar 6, 2026, 5:31 PM CET
SWX:SANN Revenue
Santhera Pharmaceuticals Holding AG had revenue of 24.01M CHF in the half year ending June 30, 2025, with 509.62% growth. This brings the company's revenue in the last twelve months to 49.02M, down -56.85% year-over-year. In the year 2024, Santhera Pharmaceuticals Holding AG had annual revenue of 39.12M, down -62.17%.
Revenue (ttm)
49.02M
Revenue Growth
-56.85%
P/S Ratio
4.61
Revenue / Employee
620.46K
Employees
79
Market Cap
226.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 39.12M | -64.30M | -62.17% |
| Dec 31, 2023 | 103.41M | 95.94M | 1,283.84% |
| Dec 31, 2022 | 7.47M | 9.07M | -568.53% |
| Dec 31, 2021 | -1.60M | -16.60M | -110.63% |
| Dec 31, 2020 | 15.01M | -60.37M | -80.09% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioVersys AG | 1.31M |
| Molecular Partners AG | 681.00K |
| Newron Pharmaceuticals | 55.93M |
| Xlife Sciences AG | 839.38K |
| Basilea Pharmaceutica AG | 232.38M |
| Idorsia | 220.58M |
| Addex Therapeutics | 158.54K |
Santhera Pharmaceuticals Holding AG News
- 7 days ago - Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain's National Health System for the Treatment of Duchenne Muscular Dystrophy - Benzinga
- 6 months ago - Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India - GlobeNewsWire
- 7 months ago - Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries - GlobeNewsWire
- 1 year ago - Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia - GlobeNewsWire
- 1 year ago - Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group - GlobeNewsWire
- 1 year ago - Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe - GlobeNewsWire